Smith & Nephew SNATS (SNN)
(Delayed Data from NYSE)
$28.52 USD
+0.17 (0.60%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $28.51 -0.01 (-0.04%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth F Momentum A VGM
Price, Consensus and EPS Surprise
SNN 28.52 +0.17(0.60%)
Will SNN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SNN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SNN
Smith & Nephew's (SNN) CATALYSTEM System Gets FDA Clearance
Smith & Nephew's (SNN) 5% Stake Acquired by Cevian Capital
SNN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Smith & Nephew's (SNN) CORIOGRAPH to Aid Arthroplasty Procedure
Smith+Nephew (SNN) Expands in Australia With New Alliance
Fresenius Medical (FMS) to Unveil Training on Augmented Reality
Other News for SNN
LONDON BROKER RATINGS: Deutsche Bank starts Smith & Nephew at 'buy'
LONDON BRIEFING: Reckitt to simplify; Informa agrees Ascential buy
Best-in-class just got better; Smith+Nephew announces 510(k) clearance of new CATALYSTEMâ„¢ Primary Hip System
Smith & Nephew announces 510(k) clearance for CATALYSTEM Primary Hip System
Smith+Nephew is trailblazing a new path for female surgeons with its Orthopaedics for All initiative; a first-of-its-kind global advisory board